Sat, Jul 26, 2014, 11:19 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Columbia Laboratories Inc. Message Board

  • onlyfactsplease onlyfactsplease Nov 9, 2012 8:46 AM Flag

    Earnings disappointment?

    I was looking for a bigger boost on revenues to signal that there would be uptake of ACOG recommendations. While better margins and foreign sales are great I don't see any real bump in US sales that makes me think there will be a sufficient uptake. I understand it's too early to see the full effect of ACOG but should be getting some traction.

    At the same time, as far as I can tell Crinone loses its patent in September of 2013...anyone know better? They did mention some bioadhesive patents extend into 2019...anyone know which ones?

    Any barriers to generic Crinone? it difficult to make? Once generic Crinone is out and used for PTB off label it will be harder to get physicians to switch to 2nd gen progesterone.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ACOG recommendations came out near the end of the quarter, so increased off-label use would show up in the 4th quarter. Meanwhile royalties from Watson hit a record already in the third quarter.

      US patent does expire Sept 2013, but generic competitors would likely need to run a non-inferiority clinical trial. By then Watson would hopefully have their superior? next gen prouct ready.

      But remember, CBRX is getting nearly 2/3 or revenue from Merck overseas, and much of that is already coming from countries where there is no patent.

      We're making 2 cents a quarter even in a seasonally slow quarter..makes 10 cents per share look easy for next year. Prochieve is done..lets get over it, and look at a very low p/e stock with nearly half the market cap in cash.

      • 1 Reply to stvwingert
      • I thought that management made some decent points on that front. Would have like to see more topline growth but hey I get that it's not a straight line. IMO management is looking to parlay the cash on hand into another rev stream. If they can execute then we could have something worthwhile. Prochieve is dead and a PTB indication for Crinone can;t be promoted. So until nextgen is developed CBRX should continue to string 3-4 .02 NI Q together.

6.23-0.12(-1.89%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.